Capecitabine/Vinorelbine: An Effective and Well-Tolerated Regimen for Women with Pretreated Advanced-Stage Breast Cancer

Nolè, Franco; Catania, Chiara; Munzone, Elisabetta; Rocca, Andrea; Verri, Elena; Sanna, Giuseppina; Ascione, G.; Adamoli, Laura; Zampino, Maria Giulia; Minchella, Ida; Goldhirsch, Aron

doi:10.3816/cbc.2006.n.005

Cited by 24 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results were encouraging and the completely oral combination achieved a response rate ranging from 39.4 to 54.8% (Nolè et al 2006(Nolè et al , 2009Estévez et al 2008 Apr). Oral chemotherapy offers significant advantages over intravenous administration because it avoids hospitalization, it is easier to administer and it does not require the use of permanent venous catheters (Campone et al 2009).…”

Section: Discussionmentioning

confidence: 85%

Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study

Oliva

Bergnolo

Inguì

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Results demonstrate that the ViFL regimen has substantial activity in patients with MBC already treated with anthracyclines and taxanes. The combination may be considered a valid choice for the treatment of MBC. Better survival results were seen in patients with visceral metastases than bone involvement. The low response rate shows that the ViFL regimen is not suitable for the neoadjuvant setting.

show abstract

Section: Discussionmentioning

confidence: 85%

Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study

Oliva

Bergnolo

Inguì

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Several combination therapies with capecitabine have been reported for patients who have already been treated using anthracyclines and/or taxanes. Nolè et al [15 ]reported vinorelbine combined with capecitabine as a tolerable option after anthracyclines and taxanes. NCCN guidelines also recently recommended ixabepilone plus capecitabine as a treatment option for MBC, as previously reported by Sparano et al [16].…”

Section: Discussionmentioning

confidence: 99%

A Phase I Study of Capecitabine Combined with CPT-11 in Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes

Kashiwaba

Inaba²,

Komatsu³

et al. 2014

Oncology

View full text Add to dashboard Cite

Objective: A dose escalation study of biweekly irinotecan (CPT-11) combined with capecitabine was performed to determine the maximum tolerated dose (MTD) and recommended dose (RD) for metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. Methods: Escalating doses of CPT-11 (80-120 mg/m²) were administered on days 1 and 15. Capecitabine was administered at a fixed dose of 1,657 mg/m²/day for 21 consecutive days, followed by 7 days of rest. We treated 3-6 patients at a particular dose level until the MTD was determined. Results: Twenty patients were treated. The MTD was determined to be 100 mg/m², as 3 of 6 patients developed dose-limiting toxicities, grade 3 leukopenia, neutropenia, photophobia, fatigue and diarrhea. The RD for the phase II study was thus determined to be 90 mg/m². The response rate was 41.7%. Conclusions: Combination therapy with CPT-11 and capecitabine was well tolerated with a promising response rate for MBC that had been treated previously with anthracyclines and taxanes. A multi-center phase II study is warranted to evaluate the efficacy and safety of this combination therapy with pharmacokinetic assessment.

show abstract

“…Capecitabine is a fluoropyrimidine carbamate that achieves higher intratumoral levels with a lower toxicity compared with 5-fluorouracil (24). Capecitabine was considered as a chemotherapeutic agent that was safe to use in patients with liver or renal disease.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study

2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract.Capecitabine is orally administered and may be safely and conveniently used in patients with cancer. The antitumor activity of capecitabine in breast cancer was mostly demonstrated in the salvage therapy setting, whereas the effect of adjuvant capecitabine monotherapy in breast cancer remains unclear. The aim of the present study was to evaluate adjuvant capecitabine monotherapy in elderly women with breast cancer. A total of 251 patients were enrolled and survival was compared between elderly breast cancer patients who received adjuvant capecitabine monotherapy and those who received no chemotherapy. Cancer-specific and disease-free survival curves were compared using log-rank tests and survival curves were calculated using the Kaplan-Meier method. Multivariate analyses were conducted using Cox's proportional hazard regression model. There was no significant difference between the clinicopathological characteristics, including age, tumor size, lymph node status, histological grade and hormone status, between patients in the two groups. The breast cancer-specific survival rate was 89.3% in the capecitabine monotherapy group vs. 81.3% in the no chemotherapy group; the difference was not statistically significant (P= 0.128). The disease-free survival rate was 81.7% in the capecitabine monotherapy group vs. 65.3% in the no chemotherapy group. Kaplan-Meier analysis indicated a longer disease-free survival in the capecitabine monotherapy group (P= 0.015). On Cox regression analysis, capecitabine monotherapy was found to be associated with the disease-free survival rate (P= 0.014, hazard ratio= 0.500) but not with the cancer-specific survival rate (P= 0.181). The adverse events of capecitabine monotherapy were recorded and there was no chemotherapy interruption due to severe adverse reactions. Therefore, adjuvant capecitabine monotherapy in elderly women with breast cancer is a safe and effective option, as well as a viable alternative for elderly breast cancer patients who refuse standard adjuvant therapy.

show abstract

Capecitabine/Vinorelbine: An Effective and Well-Tolerated Regimen for Women with Pretreated Advanced-Stage Breast Cancer

Cited by 24 publications

References 24 publications

Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study

Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study

A Phase I Study of Capecitabine Combined with CPT-11 in Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes

Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study

Contact Info

Product

Resources

About